CJC-1295 & Ipamorelin Australia 2026: Research Guide, Dosing & Where to Buy

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH), the endogenous hypothalamic peptide that drives pituitary GH secretion. Native GHRH has a plasma half-life of less than 10 minutes, rapidly inactivated by dipeptidyl peptidase IV (DPP-IV). CJC-1295 was developed by ConjuChem to overcome this limitation through two key modifications:

• DPP-IV resistance, amino acid substitutions at positions 2 and 8 protect the peptide from enzymatic cleavage
• Drug Affinity Complex (DAC) technology, a reactive lysine residue allows covalent binding to endogenous albumin after injection, extending the half-life to approximately 6–8 days

The result is a GHRH analogue that produces sustained GHRH signalling from a single weekly injection. CJC-1295 without DAC (also called Modified GRF 1-29 or Mod-GRF) retains the DPP-IV-resistant modifications but lacks the albumin-binding DAC, giving a half-life of approximately 30 minutes and producing a more physiological pulsatile GH pattern.

DAC vs No-DAC: Which for Research? CJC-1295 with DAC produces sustained GH elevation (constant signal, once-weekly dosing). CJC-1295 without DAC produces sharp GH pulses resembling physiological pulsatility (multiple daily doses required). The research question determines the choice: sustained GH effects → use DAC; pulsatile GH physiology → use no-DAC with Ipamorelin.

Ipamorelin is a synthetic pentapeptide and selective growth hormone secretagogue receptor (GHSR-1a) agonist, the receptor targeted by the endogenous hunger hormone ghrelin. It was developed as a research tool to study ghrelin-pathway-mediated GH release without the off-target effects of earlier GHRPs.

What makes Ipamorelin particularly valuable in research is its selectivity profile. Earlier GHRPs, GHRP-2 and GHRP-6, are potent GH releasers but also significantly stimulate cortisol, ACTH, and prolactin secretion, confounding research that aims to isolate GH-axis effects. Ipamorelin produces robust GH release with minimal effect on these hormones at research doses:

Ipamorelin's high GH selectivity makes it the preferred GHRP in combination protocols with CJC-1295, where the research aim is GH/IGF-1 axis stimulation with minimal confounding hormonal changes.

The combination of a GHRH analogue (CJC-1295) and a GHRP (Ipamorelin) exploits two distinct but complementary receptor systems that converge on pituitary somatotroph cells to trigger GH release:

• GHRH receptor (CJC-1295 target), increases intracellular cAMP, promoting GH synthesis and secretion; also sensitises the somatotroph to subsequent GH-releasing stimuli
• GHSR-1a / ghrelin receptor (Ipamorelin target), activates a separate signalling cascade via phospholipase C / PKC, triggering GH vesicle release through a calcium-dependent mechanism

Key Research Finding: Synergistic GH Release GH release from combined GHRH + GHRP administration is not merely additive, it is synergistic. Published research has demonstrated that combining a GHRH analogue with a GHRP produces GH pulses 2–10× greater than either compound alone. This synergy is the primary rationale for the CJC-1295/Ipamorelin combination in research protocols.

The combination also closely mimics the physiology of natural GH pulsatility, which is driven by the simultaneous interaction of hypothalamic GHRH (a pulse-generating signal) and circulating ghrelin (an amplitude-modulating signal) at the pituitary. This physiological similarity makes the CJC-1295 + Ipamorelin combination a useful research tool for studying GH axis dynamics.

Research on CJC-1295, Ipamorelin, and their combination spans human Phase 2 clinical data and extensive preclinical evidence. Key findings by research area:

The Phase 2 clinical data for CJC-1295 alone (Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006) provides the strongest human evidence base. It demonstrated that a single injection produced mean GH increases of 2–10-fold and IGF-1 increases of 1.5–3-fold persisting for 6–7 days, consistent with the albumin-binding pharmacokinetics of the DAC formulation.

The two forms of CJC-1295 have meaningfully different pharmacokinetic profiles that determine their research applications:

Most combination protocols with Ipamorelin use CJC-1295 without DAC, since the pulsatile pattern from simultaneous GHRH + GHRP administration most closely mimics physiological GH release. CJC-1295 with DAC is more commonly used in protocols studying sustained GH/IGF-1 elevation independent of pulse dynamics.

Published and documented research protocols for CJC-1295 and Ipamorelin use the following dose ranges. These represent doses used in published studies and documented research protocols, not clinical recommendations:

Combination Protocol Note When used in combination, CJC-1295 without DAC and Ipamorelin are typically administered simultaneously to maximise the synergistic GH pulse. Pre-sleep timing aligns with the largest endogenous GH pulse of the day, amplifying rather than disrupting physiological GH pulsatility, making it the most common timing in research protocols.

In published research and documented protocol reports, the CJC-1295/Ipamorelin combination produces time-dependent changes across metabolic and body composition endpoints:

IGF-1 as Research Biomarker IGF-1 (insulin-like growth factor 1) is the primary measurable downstream biomarker of GH-axis stimulation. In CJC-1295 Phase 2 trials, IGF-1 increases of 1.5–3× from baseline were documented within 7 days of a single injection and sustained throughout the dosing period. IGF-1 is the standard quantitative endpoint in GH secretagogue research.

The adverse event profile of CJC-1295 and Ipamorelin in research is generally mild and transient. The most commonly reported events from clinical and preclinical data:

In the Phase 2 clinical trial of CJC-1295 (Teichman et al., JCEM 2006), adverse events were mild and no serious adverse events were attributed to the study drug. The tolerability profile was considered favourable for a GH secretagogue candidate.

CJC-1295 and Ipamorelin are each supplied as lyophilised powder in separate vials. Standard reconstitution procedure for each:

1. Allow sealed vials to reach room temperature before opening
2. Add bacteriostatic water slowly down the inside wall of the vial, do not inject directly onto the powder
3. Gently swirl (do not shake) until the powder is fully dissolved
4. For a 2mg CJC-1295 vial with 2mL bacteriostatic water: concentration = 1mg/mL (1,000mcg/mL)
5. For a 5mg Ipamorelin vial with 2.5mL bacteriostatic water: concentration = 2mg/mL (2,000mcg/mL)
6. Store reconstituted vials at 2–8°C; label with date of reconstitution; use within 28 days

Both peptides are colourless once reconstituted. A slight haze that clears on gentle warming is normal for the CJC-1295 DAC formulation. Discard any solution that remains cloudy or has visible particulate matter.

Use OzPeps' free reconstitution calculator to calculate volumes and concentrations for any vial size or target dose.

What is the difference between CJC-1295 with DAC and without DAC?

CJC-1295 with DAC binds to albumin after injection, extending half-life to ~6–8 days, allowing once-weekly dosing and sustained GH/IGF-1 elevation. CJC-1295 without DAC (Mod-GRF 1-29) has a ~30-minute half-life, producing sharper, more physiological GH pulses. DAC is used for sustained GH restoration studies; no-DAC is used for pulsatile GH dynamics research, typically combined with Ipamorelin.

Why combine CJC-1295 with Ipamorelin?

The combination activates two separate receptor pathways, GHRH receptor (CJC-1295) and GHSR-1a ghrelin receptor (Ipamorelin), that produce synergistic GH release when activated simultaneously. Research has demonstrated the combination produces GH pulses 2–10× greater than either compound alone, closely mimicking the dual-signal mechanism of physiological GH pulsatility.

Is CJC-1295 available in Australia?

Research-grade CJC-1295 (both DAC and no-DAC formulations) is available from Australian suppliers for laboratory research. OzPeps stocks CJC-1295 and Ipamorelin for documented research use. Neither compound is TGA-approved as a therapeutic medicine in Australia.

What does Ipamorelin do?

Ipamorelin is a selective GHSR-1a agonist (ghrelin receptor agonist) that triggers GH release from the pituitary without significantly affecting cortisol, ACTH, or prolactin. In combination with CJC-1295, it produces synergistic GH pulses. Its selectivity is its key distinguishing feature versus earlier GHRPs (GHRP-2, GHRP-6) which have broader hormonal effects.

How long does it take to see results in research models?

IGF-1 elevation (the primary measurable biomarker) is detectable within 72 hours of a CJC-1295 dose. The Phase 2 study (Teichman et al., 2006) showed sustained IGF-1 elevation of 1.5–3× baseline throughout the 6-week study period. Body composition changes documented in published protocols typically became measurable at 8–12 weeks.

What are the side effects of CJC-1295 and Ipamorelin?

The Phase 2 CJC-1295 trial reported mild, transient adverse events: headache, flushing, and water retention were the most common, all self-limiting. Ipamorelin's primary transient effects are brief flushing after injection (GH-pulse vasodilation) and mild increased hunger (ghrelin receptor mechanism). No serious adverse events were attributed to either compound in published research at standard doses.

How do you reconstitute CJC-1295 and Ipamorelin?

Add bacteriostatic water slowly down the inside wall of the vial and gently swirl until dissolved. For a 2mg CJC-1295 vial: 2mL bacteriostatic water = 1mg/mL. For a 5mg Ipamorelin vial: 2.5mL = 2mg/mL. Store at 2–8°C and use within 28 days. Use the OzPeps reconstitution calculator for precise volumes.

Can CJC-1295 and Ipamorelin be mixed in the same syringe?

Research protocols document both compounds being drawn into the same syringe for simultaneous administration. Both peptides are stable in bacteriostatic water when stored separately at 2–8°C. Keep reconstituted solutions in separate vials and combine in the syringe at the time of use, do not pre-mix and store in the same vial.

OzPeps supplies research-grade CJC-1295 and Ipamorelin Australia-wide with Certificate of Analysis documentation, fast dispatch, and Express Post shipping.

CJC-1295 / Ipamorelin →

Related guides: Ipamorelin standalone research guide → · GH peptides vs HGH: what the research shows →

All CJC-1295 and Ipamorelin products sold by OzPeps are supplied strictly for laboratory and in-vitro research purposes. They are not TGA-approved therapeutic goods, are not intended for human or animal consumption, and are not sold for diagnostic or treatment purposes. Researchers are responsible for compliance with all applicable regulations.